CRMD
Price
$8.10
Change
+$0.31 (+3.98%)
Updated
Oct 22 closing price
Capitalization
631.35M
20 days until earnings call
Intraday BUY SELL Signals
RLYB
Price
$16.40
Change
+$0.18 (+1.11%)
Updated
Oct 22, 04:24 PM (EDT)
Capitalization
86.17M
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRMD vs RLYB

CRMD vs RLYB Comparison Chart in %
View a ticker or compare two or three
VS
CRMD vs. RLYB commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRMD is a StrongBuy and RLYB is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CRMD with price predictions
Oct 22, 2026

CRMD in upward trend: price rose above 50-day moving average on October 22, 2026

CRMD moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 29 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on CRMD as a result. In 64 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for CRMD just turned positive on October 15, 2026. Looking at past instances where CRMD's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.

The 50-day moving average for CRMD moved above the 200-day moving average on October 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +7.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMD advanced for three days, in 228 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The 10-day moving average for CRMD crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

CRMD broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CRMD entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. CRMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 77 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.370) is normal, around the industry mean (2.973). P/E Ratio (3.293) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (5.636) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.564) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for RLYB with price predictions
Oct 21, 2026

RLYB sees MACD Histogram just turned negative

RLYB saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 01, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 42 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RLYB as a result. In 83 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.

RLYB moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RLYB crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLYB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for RLYB entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where RLYB advanced for three days, in 238 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

RLYB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 18 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. RLYB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.912) is normal, around the industry mean (2.988). P/E Ratio (2.017) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (147.059) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLYB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CRMD: Fundamental Ratings
CRMD
OUTLOOK RATING
1..100
43
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
PROFIT vs RISK RATING
1..100
77
SMR RATING
1..100
19
PRICE GROWTH RATING
1..100
59
P/E GROWTH RATING
1..100
96
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRMDRLYB
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 21 days ago
85%
Bearish Trend 7 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 2 days ago
87%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (CRMD: $8.10 vs. RLYB: $16.22)
Brand notoriety: CRMD and RLYB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRMD: 98% vs. RLYB: 181%
Market capitalization -- CRMD: $631.35M vs. RLYB: $86.49M
CRMD [@Biotechnology] is valued at $631.35M. RLYB’s [@Biotechnology] market capitalization is $86.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRMD’s FA Score shows that 1 FA rating(s) are green while RLYB’s FA Score has 1 green FA rating(s).

  • CRMD’s FA Score: 1 green, 4 red.
  • RLYB’s FA Score: 1 green, 4 red.
According to our system of comparison, RLYB is a better buy in the long-term than CRMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRMD’s TA Score shows that 5 TA indicator(s) are bullish while RLYB’s TA Score has 3 bullish TA indicator(s).

  • CRMD’s TA Score: 5 bullish, 6 bearish.
  • RLYB’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CRMD is a better buy in the short-term than RLYB.

Price Growth

CRMD (@Biotechnology) experienced а +8.58% price change this week, while RLYB (@Biotechnology) price change was -4.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

CRMD is expected to report earnings on Nov 11, 2026.

RLYB is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.